181 related articles for article (PubMed ID: 18755171)
1. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.
Gavelová M; Hladíková J; Vildová L; Novotná R; Vondrácek J; Krcmár P; Machala M; Skálová L
Chem Biol Interact; 2008 Oct; 176(1):9-18. PubMed ID: 18755171
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases.
Hofman J; Skarka A; Havrankova J; Wsol V
Biochem Pharmacol; 2015 Aug; 96(3):168-78. PubMed ID: 25986883
[TBL] [Abstract][Full Text] [Related]
3. The influence of oracin on reduction and toxicity of doxorubicin in hepatocytes and mammary epithelial cells MCF-10A.
Hanušová V; Boušová I; Pakostová A; Skálová L
Xenobiotica; 2012 Jun; 42(6):571-9. PubMed ID: 22217270
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of oracin in enhancing the cytotoxicity of doxorubicin through the inhibition of doxorubicin deactivation in breast cancer MCF7 cells.
Hanusová V; Králová V; Schröterová L; Trilecová L; Pakostová A; Skálová L
Xenobiotica; 2010 Oct; 40(10):681-90. PubMed ID: 20698750
[TBL] [Abstract][Full Text] [Related]
5. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
6. Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin.
Skarydová L; Skarka A; Novotná R; Zivná L; Martin HJ; Wsól V; Maser E
Toxicology; 2009 Oct; 264(1-2):52-60. PubMed ID: 19635524
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
Novotna R; Wsol V; Xiong G; Maser E
Toxicol Lett; 2008 Sep; 181(1):1-6. PubMed ID: 18616992
[TBL] [Abstract][Full Text] [Related]
8. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
9. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man.
Wsol V; Szotakova B; Martin HJ; Maser E
Toxicology; 2007 Sep; 238(2-3):111-8. PubMed ID: 17618725
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells.
Akman SA; Forrest G; Chu FF; Esworthy RS; Doroshow JH
Cancer Res; 1990 Mar; 50(5):1397-402. PubMed ID: 2406012
[TBL] [Abstract][Full Text] [Related]
11. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver.
Kassner N; Huse K; Martin HJ; Gödtel-Armbrust U; Metzger A; Meineke I; Brockmöller J; Klein K; Zanger UM; Maser E; Wojnowski L
Drug Metab Dispos; 2008 Oct; 36(10):2113-20. PubMed ID: 18635746
[TBL] [Abstract][Full Text] [Related]
12. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Grigliatti TA; Reid RE; Riggs KW
J Pharmacol Exp Ther; 2010 Dec; 335(3):533-45. PubMed ID: 20837989
[TBL] [Abstract][Full Text] [Related]
13. A comparison between stereospecificity of oracin reduction and stereoselectivity of oxidation of 11-dihydrooracin enantiomers in vitro in rat and guinea pig.
Skálová L; Wsól V; Szotáková B; Kvasnicková E
Chirality; 1999; 11(5-6):510-5. PubMed ID: 10368925
[TBL] [Abstract][Full Text] [Related]
14. Up-Regulation of Carbonyl Reductase 1 Renders Development of Doxorubicin Resistance in Human Gastrointestinal Cancers.
Matsunaga T; Kezuka C; Morikawa Y; Suzuki A; Endo S; Iguchi K; Miura T; Nishinaka T; Terada T; El-Kabbani O; Hara A; Ikari A
Biol Pharm Bull; 2015; 38(9):1309-19. PubMed ID: 26328486
[TBL] [Abstract][Full Text] [Related]
15. In vivo effect of oracin on doxorubicin reduction, biodistribution and efficacy in Ehrlich tumor bearing mice.
Hanušová V; Tomšík P; Kriesfalusyová L; Pakostová A; Boušová I; Skálová L
Pharmacol Rep; 2013; 65(2):445-52. PubMed ID: 23744429
[TBL] [Abstract][Full Text] [Related]
16. Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases.
Malátková P; Sokolová S; Chocholoušová Havlíková L; Wsól V
Biochem Pharmacol; 2016 Jun; 109():83-90. PubMed ID: 27055738
[TBL] [Abstract][Full Text] [Related]
17. Stereospecific reduction of the original anticancer drug oracin in rat extrahepatic tissues.
Szotáková B; Skálová L; Jílek P; Buchta V; Wsól V
J Pharm Pharmacol; 2003 Jul; 55(7):1003-11. PubMed ID: 12906758
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence studies of tibolone in premenopausal women and effects on expression of the tibolone-metabolizing enzyme AKR1C (aldo-keto reductase) family caused by estradiol.
Kang KW; Kim YG
J Clin Pharmacol; 2008 Dec; 48(12):1430-7. PubMed ID: 18832293
[TBL] [Abstract][Full Text] [Related]
19. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
Ghosal A; Yuan Y; Tong W; Su AD; Gu C; Chowdhury SK; Kishnani NS; Alton KB
Drug Metab Dispos; 2011 Mar; 39(3):510-21. PubMed ID: 21123164
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
